Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.32 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.31 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.31 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 6/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ESRRA | P11474 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6371296 | 0.99 | PDPK1 (0.35) | PDPK1HPGDKDM4EALDH1A1THRB | |
| Hydrochloric Acid SCHEMBL2673746 | 0.85 | SMN1; SMN2 (0.41) | HPGDKDM4EALDH1A1NPC1TP53 | |
| SCHEMBL6371362 | 0.84 | KDM4E (0.41) | HPGDKDM4EALDH1A1NPC1TP53 | |
| Hydrochloric Acid SCHEMBL2674434 | 0.84 | ALDH1A1 (0.39) | HPGDKDM4EALDH1A1EP300NPC1 | |
| SCHEMBL5710061 | 0.83 | ALDH1A1 (0.40) | HPGDKDM4EALDH1A1EP300NPC1 | |
| Hydrochloric Acid SCHEMBL5710182 | 0.82 | ACHE (0.40) | TP53 | |
| Hydrochloric Acid SCHEMBL2674531 | 0.82 | SMN1; SMN2 (0.37) | HPGDKDM4EALDH1A1EP300NPC1 | |
| Hydrochloric Acid SCHEMBL2673336 | 0.82 | EP300 (0.34) | HPGDKDM4EALDH1A1EP300SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2674209 | 0.82 | CD274 (0.39) | ALDH1A1CA2HDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL2674064 | 0.81 | OPRM1 (0.35) | HPGDKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108409651-B | Method for preparing 8-hydroxy-2-methylquinoline by using waste residue of chloroquinate | 北京金城泰尔制药有限公司沧州分公司 | 2021-03-02 | — | — | CN | claimed |
| CN-110845407-A | Preparation method of chloroquinate crystal | 北京金城泰尔制药有限公司 | 2020-02-28 | — | — | CN | claimed |
| EP-1732896-B1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMA INC (US) | 2012-12-12 | — | — | EP | claimed |
| US-20120202795-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-09 | — | — | US | claimed |
| US-20070032489-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2007-02-08 | — | — | US | claimed |
| EP-1732896-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | Aventis Pharmaceuticals Inc. (US) | 2006-12-20 | — | — | EP | claimed |
| WO-2005097750-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | claimed |
| CN-119875972-A | Methods and compositions for preventing microbial infection | 比奥普来克斯有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-111918960-B | Methods and compositions for preventing microbial infection | 比奥普来克斯有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-118750495-A | Application of chlorquinaldo | 广州医科大学 | 2024-10-11 | — | — | CN | disclosed |
| CN-115916752-A | Aryltetrahydropyridine derivatives or salts thereof, and pesticides containing the same and methods of use thereof | 日本农药株式会社 | 2023-04-04 | — | — | CN | disclosed |
| CN-112521334-B | Method for preparing 8-hydroxy-2-methylquinoline based on chloroquinate waste residue | 北京金城泰尔制药有限公司沧州分公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-114081883-A | Application of cloquindol in preparation of antitumor drugs | 武汉科技大学 | 2022-02-25 | — | — | CN | disclosed |
| US-20070032489-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1339725-B1 | DNA METHYL TRANSFERASE INHIBITORS | PENN STATE RES FOUND (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050227933-A1 | Treatment of bacterial induced diseases using DNA methyl transferase inhibitors | BENKOVIC STEPHEN J | 2005-10-13 | — | — | US | disclosed |
| EP-1339725-A2 | DNA METHYL TRANSFERASE INHIBITORS | THE PENN STATE RESEARCH FOUNDATION (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002044184-A2 | DNA METHYL TRANSFERASE INHIBITORS | THE PENN STATE RESEARCH FOUNDATION (US) | 2002-06-06 | — | — | WO | disclosed |
| JP-2000281651-A | SEPARATION OF QUINALDINE DERIVATIVE | SUMIKIN CHEMICAL CO LTD | 2000-10-10 | — | — | JP | disclosed |
| US-5274096-A | Hydrazine synthesis | MERCK & CO., INC. (US) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202795-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP2, PARP3 | HDAC6 1821/4885CA2 4624/4885ROCK1 963/4885 |
| US-20070032489-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP2, PARP3 | HDAC6 1821/4885CA2 4624/4885ROCK1 963/4885 |
| US-20050227933-A1 | Treatment of bacterial induced diseases using DNA methyl transferase inhibitors | DNMT1, TPMT, GNMT | HDAC6 492/4885CA2 3114/4885ROCK1 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.